secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001213900-24-021573
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024
--------------------------------------------------------------------------------

- Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.
- Full year 2023 net loss $46.3M ($0.91/sh) vs $29.7M ($0.74/sh) in 2022.
- FDA approved DefenCath Nov 15, 2023; commercial launch in inpatient setting planned April 15, 2024.
- CMS TDAPA application under review; targeting July 1, 2024 outpatient launch.
- Cash and short-term investments $76.0M at Dec 31, 2023; sufficient for at least 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/ea0201559-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-021573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer